Thursday, December 22, 2016

Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease

Searching in Google Scholar found one mention for an intervention for apathy after stroke.

Successful treatment of post-stroke apathy by the dopamine receptor agonist ropinirole

The Sydney Stroke Study found 26-7% of stroke patients reported apathy. With that frequency it is criminal if your doctor has no treatment plan.
http://journals.sagepub.com/doi/abs/10.1177/0891988716678684

A Systematic Review Across Modalities

First Published December 16, 2016 review-article



Apathy is one of the most frequent neuropsychiatric symptoms encountered in Alzheimer disease (AD). Early diagnosis and timely treatment of apathy in AD seem to be of great importance, since apathy has been associated with poor disease outcome, reduced daily functioning, and caregiver distress.

Within this context, we conducted an extensive electronic search from the databases included in the National Library of Medicine as well as PsychInfo and Google Scholar for studies that have investigated the effect of pharmacological and nonpharmacological treatments of apathy in AD.

Acetylcholinesterase inhibitors, gingko biloba, methylphenidate, and a variety of nonpharmacological interventions were found to be successful in reducing apathy in patients with AD. Methodological heterogeneity of the studies and the small amount of studies where apathy was a primary outcome measure are limiting factors to evaluate for group effects.

Treatment of apathy in AD is a complicated and an underexplored field. Standardized and systematic efforts primarily focused on the study of apathy in AD may establish a benefit from individualized treatment for specific disease groups that would stem from a combination of both pharmacological and nonpharmacological interventions.

155 references so maybe your doctor can make some conclusions from them to help you not have apathy in your stroke rehab.

No comments:

Post a Comment